ATE311202T1 - Kationische dendrimer verbindungen und deren verwendung als oligonucleotid/polynucleotid träger - Google Patents
Kationische dendrimer verbindungen und deren verwendung als oligonucleotid/polynucleotid trägerInfo
- Publication number
- ATE311202T1 ATE311202T1 AT99947667T AT99947667T ATE311202T1 AT E311202 T1 ATE311202 T1 AT E311202T1 AT 99947667 T AT99947667 T AT 99947667T AT 99947667 T AT99947667 T AT 99947667T AT E311202 T1 ATE311202 T1 AT E311202T1
- Authority
- AT
- Austria
- Prior art keywords
- oligonucleotide
- dna
- cells
- sub
- cationic dendrimer
- Prior art date
Links
- 239000000412 dendrimer Substances 0.000 title abstract 3
- 229920000736 dendritic polymer Polymers 0.000 title abstract 3
- 108091034117 Oligonucleotide Proteins 0.000 title 1
- 239000000969 carrier Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 108091033319 polynucleotide Proteins 0.000 title 1
- 102000040430 polynucleotide Human genes 0.000 title 1
- 239000002157 polynucleotide Substances 0.000 title 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 abstract 1
- 125000000266 alpha-aminoacyl group Chemical group 0.000 abstract 1
- 125000002091 cationic group Chemical group 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 238000001890 transfection Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
- C08G83/002—Dendritic macromolecules
- C08G83/003—Dendrimers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/641—Branched, dendritic or hypercomb peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Polymers & Plastics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polyamides (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98307712 | 1998-09-23 | ||
| GBGB9921478.5A GB9921478D0 (en) | 1999-09-10 | 1999-09-10 | Cationic compounds and their use as macro molecular carriers |
| PCT/GB1999/003189 WO2000016807A1 (en) | 1998-09-23 | 1999-09-23 | Cationic compounds and their use as macro molecular carriers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE311202T1 true ATE311202T1 (de) | 2005-12-15 |
Family
ID=26151448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99947667T ATE311202T1 (de) | 1998-09-23 | 1999-09-23 | Kationische dendrimer verbindungen und deren verwendung als oligonucleotid/polynucleotid träger |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7081495B1 (de) |
| EP (1) | EP1115428B1 (de) |
| JP (1) | JP2002526456A (de) |
| AT (1) | ATE311202T1 (de) |
| DE (1) | DE69928679T2 (de) |
| WO (1) | WO2000016807A1 (de) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0220936D0 (en) | 2002-09-05 | 2002-10-23 | Adprotech Ltd | Modified therapeutic agents |
| EP1796537A4 (de) * | 2004-08-25 | 2012-03-07 | Univ Michigan | Dendrimer-basierte zusammensetzungen und verfahren zu ihrer verwendung |
| FR2885130B1 (fr) * | 2005-04-28 | 2007-06-29 | Centre Nat Rech Scient | Procede de preparation de polylysines dendrimeres greffes |
| JP4870941B2 (ja) * | 2005-05-09 | 2012-02-08 | 公立大学法人大阪府立大学 | 高分子化合物 |
| EP1733742A1 (de) * | 2005-06-17 | 2006-12-20 | Universiteit Utrecht Holding B.V. | Durch aktive Gruppen multivalent-substituierte Dendrimere |
| WO2010039861A2 (en) | 2008-09-30 | 2010-04-08 | The Regents Of The University Of Michigan | Dendrimer conjugates |
| US9017644B2 (en) | 2008-11-07 | 2015-04-28 | The Regents Of The University Of Michigan | Methods of treating autoimmune disorders and/or inflammatory disorders |
| CN102917699A (zh) | 2009-10-13 | 2013-02-06 | 密执安大学评议会 | 树枝状聚合物组合物和合成方法 |
| US8912323B2 (en) | 2009-10-30 | 2014-12-16 | The Regents Of The University Of Michigan | Multifunctional small molecules |
| JP5346307B2 (ja) * | 2010-03-03 | 2013-11-20 | 独立行政法人科学技術振興機構 | タンパク質の細胞内導入のためのポリイオンデンドリマー |
| US9402911B2 (en) | 2011-12-08 | 2016-08-02 | The Regents Of The University Of Michigan | Multifunctional small molecules |
| US10869939B2 (en) * | 2015-08-03 | 2020-12-22 | Ramot At Tel-Aviv University Ltd. | Delivery system in micellar form having modular spectral response based on enzyme-responsive amphiphilic PEG-dendron hybrid polymers |
| JP7768775B2 (ja) * | 2021-01-14 | 2025-11-12 | 出光興産株式会社 | ペプチドタグおよびそれを含むタグ付加タンパク質 |
| CN113563429A (zh) * | 2021-07-19 | 2021-10-29 | 天津大学 | 一种基于烷基化多肽的核酸递送系统及制备方法与应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9215780D0 (en) * | 1992-07-24 | 1992-09-09 | Univ London Pharmacy | Peptide compounds |
| US6051429A (en) * | 1995-06-07 | 2000-04-18 | Life Technologies, Inc. | Peptide-enhanced cationic lipid transfections |
| EP0884327B1 (de) * | 1997-06-11 | 2001-03-14 | The School Of Pharmacy, University Of London | Dendritische, lysinhaltige Polypeptide zur gezielten Arzneimittelabreichung |
-
1999
- 1999-09-23 AT AT99947667T patent/ATE311202T1/de not_active IP Right Cessation
- 1999-09-23 WO PCT/GB1999/003189 patent/WO2000016807A1/en not_active Ceased
- 1999-09-23 JP JP2000573768A patent/JP2002526456A/ja not_active Withdrawn
- 1999-09-23 US US09/786,091 patent/US7081495B1/en not_active Expired - Fee Related
- 1999-09-23 DE DE69928679T patent/DE69928679T2/de not_active Expired - Fee Related
- 1999-09-23 EP EP99947667A patent/EP1115428B1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1115428A1 (de) | 2001-07-18 |
| WO2000016807A1 (en) | 2000-03-30 |
| US7081495B1 (en) | 2006-07-25 |
| DE69928679D1 (de) | 2006-01-05 |
| EP1115428B1 (de) | 2005-11-30 |
| JP2002526456A (ja) | 2002-08-20 |
| DE69928679T2 (de) | 2006-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE311202T1 (de) | Kationische dendrimer verbindungen und deren verwendung als oligonucleotid/polynucleotid träger | |
| ES2962434T3 (es) | Procedimientos y composiciones para editar ARN | |
| Gewirtz et al. | Facilitating oligonucleotide delivery: helping antisense deliver on its promise. | |
| ES2243608T5 (es) | Procedimiento y medicamento para la inhibición de la expresión de un gen predeterminado | |
| Suter et al. | Double-target antisense U7 snRNAs promote efficient skipping of an aberrant exon in three human β-thalassemic mutations | |
| Fabani et al. | Efficient inhibition of miR-155 function in vivo by peptide nucleic acids | |
| Katayose et al. | Water-soluble polyion complex associates of DNA and poly (ethylene glycol)− poly (l-lysine) block copolymer | |
| AU2024205204A1 (en) | Synthetic guide molecules, compositions and methods relating thereto | |
| ES2616561T3 (es) | Molécula para tratar un trastorno inflamatorio | |
| ATE237312T1 (de) | In liposomen verkapselte nukleinsäurekomplexe | |
| CA2416289A1 (en) | Multi-component biological transport systems | |
| WO2015148860A1 (en) | Crispr/cas-related methods and compositions for treating beta-thalassemia | |
| Bahal et al. | Nanoparticle for delivery of antisense γPNA oligomers targeting CCR5 | |
| BR0108959A (pt) | Composições de poloxmero ou poloxamina melhoradas para distribuição de ácido nucléico | |
| Xu et al. | Folic acid-decorated polyamidoamine dendrimer mediates selective uptake and high expression of genes in head and neck cancer cells | |
| US20210121580A1 (en) | Functionalized DNA Dendrimers For Gene Delivery To Cells | |
| Moccia et al. | Insights on chiral, backbone modified peptide nucleic acids: properties and biological activity | |
| US20210188895A1 (en) | Single-stranded nucleic acid molecule, and production method therefor | |
| Rapozzi et al. | Antigene effect in K562 cells of a PEG-conjugated triplex-forming oligonucleotide targeted to the bcr/abl oncogene | |
| Gonçalves et al. | An optimized extended DNA kappa B site that enhances plasmid DNA nuclear import and gene expression | |
| DK1175489T3 (da) | Oligonukleotider indeholdende en antisense-sekvens stabiliseret af en sekundær struktur og farmaceutiske præparater indeholdende disse oligonukleotider | |
| Suzuki et al. | Poly (ethylene Glycol)(PEG)–OligoRNA Hybridization to mRNA Enables Fine‐Tuned Polyplex PEGylation for Spleen‐Targeted mRNA Delivery | |
| Breitenkamp et al. | Pentalysine-grafted ROMP polymers for DNA complexation and delivery | |
| US20200263206A1 (en) | Targeted integration systems and methods for the treatment of hemoglobinopathies | |
| Svahn et al. | Adding functional entities to plasmids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |